Журнал. Вестник офтальмологии № 6 — 2020 г.

________________ _________________ Literature reviews

Обзоры литературы

29. Roberts CW, Brennan KM. A comparison o f topical diclofenac with pred­ nisolone for postcataract inflammation. Arch Ophthal. 1995;113:725-727. https://doi.org/10.1001/archopht.1995.01100060051031 30. EL-Harazi SM, Ruiz RS, Feldman RM, Villanueva G , Chuang AZ. A ran­ domized double — masked trial comparing ketorolac tromethamine 0.5%, di­ clofenac sodium 0 . 1 %, and prednisolone acetate 1 % in reducing post phaco­ emulsification flare and cells. Ophthalmic Su/g Lasers. 1998;29:539-544. 31. Flach FJ. Nonstero idal an ti-in f lamm a to ry drugs. In: Tasman W, editor. Duane’s foundations o f clinical ophthalmology. Philadelphia (PA): Lippin- cott; 1994. 32. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence o f visually sig­ nificant pseudophakic macu lar edema after uneventful phacoemu lsifica­ tion in patients treated with nepafenac. J Cataract Refract Su/g. 2007;33(9): 1546-1549. h ttps://do i .O rg /10 .1016 /j.jcrs .2007 .05 .018 33. Heier JS, Topping TM , Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the trea tm en t o f acute pscudo- phakic cystoid macular edema. Ophthalmology. 2000;107:2034-2039. https://doi.org/10.1016/s0l6l-6420(00)00365-1 34. Abdel-Latif AA. Regulation o f arachidonate release, prostaglandin synthe­ sis, and sphincter constriction in the mammalian iris-cyliary body, prog Clin Biol Res. 1989;312:53-72. 35. Мальханов В.Б., Шевчук H .E ., Абсаликова Д .К . Динамика интерлей­ кина 1-бета и простагландина Е2 при эндогенных увеитах. Рефракци­ онная хирургия и офтальмология. 2010; 1:40-42. M a l’hanov VB, Shevchuk NE , Absalikova DK. Dynamics o f interleukin 1-Beta and prostaglandin E2 with endogenous uveitis. Refraccionnaya hirur- giya i oftalmologiya. 2010;1:40-42. (In Russ.). 36. Bucolo C, Marrazzo G , Platania CB, Romano GL, Drago F, Salomone S. Ef­ fects o f topical indometacin, bromfenac and nepafenac on lipopolysaccharide- induced ocular inflammation. J Pharm Pharmacol. 2014;66(7):954-960. https://doi.org/10.1111/jphp. 12224 37. Weber V, Kodjikian I, Kruse FE, Zagorski Z, Allaire CM. Efficacy and safety o f indomethacin 0.1% eye drops compared with ketorolak 0.5% eye drops in the management o f ocular inflammation after cataract surgery. Acta Ophthal­ mol. 2013;91( 1): 15-21. 38. Yavas GF, Oztiirk F, Kiisbeci T. Preoperative top ical in d om e th a c in to prevent p seudoph ak ic cystoid edem a . J Cataract Refract Sutg. 2007 ;33(5):804-807 . h ttps://do i .O rg /10 .1016 /j.jc rs .2007 .01 .033 39. Allegri P, Murialdo U, Peri S, Carniglia R, Crivelli MG ,e t al. Randomized double blind, placebo-controlled clinical trail on the efficacy o f 0.5% indo ­ me thacin eye drops in uveitic m acu lar edema. Invest Ophthalmol vis Sci. 2014;55(3): 1463-1470. https://doi.org/10.1167/iovs.13-13202 40. Cho H, Wolf KJ, Wolf EJ. Management o f ocular inflammation and pain following cataract surgery: focus on bromfenac oph tha lm ic solution. Clin Ophthalmol. 2009;3:199-210. https://doi.org/10.2147/opth.s4806 41. Александрова О .И ., Околов И .Н . , Хорольская Ю .И ., П анова И .Е ., Блинова М.И. Влияние нестсроидных противовоспалительных глаз­ ных капель на клетки эпителия роговицы и конъюнктивы человека в условиях in vitro. Офтальмология. 2017; 15(3):251-259. Aleksandrova OI, Okolov IN, Khorolskaya Yul, Panova IE, Blinova MI. In­ fluence o f Nonsteroidal Anti-inflammatory Eye Drops on the Epithelium Cells o f the Cornea and Conjunctiva in vitro. Oftal’mologiya. 2017; 15(3):251 - 259. (In Russ.). https://doi.org/10.18008/1816-5095-2017-3-251-259 42. Baranovski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic Drug Dosage Forms: Characterisation and Research Methods. The ScientificWorld Jour­ nal. 2014. https://doi.org/10.1155 /2014/861904 43. Морозов В. И . Гемато-офтальмический барьер: структурно-функциональ­ ные особенности. РМЖ Клиническая офтальмология. 2017; 10(4):68-72. Morozov VI. A gem a to-ophthalm ic barrier: structural and functional fea­ tures. RMZ. Klinicheskaya oftal'mologiya. 2017; 10(4):68-72. (In Russ.). 44. Насонов Е.Л. Нестероидные противовоспалительные препараты: но­ вые аспекты применения в ревматологии и кардиологии. Русскии ме­ дицинский журнал. 2003; 11(23): 1280-1284. Nasonov EL. Non-steroidal Anti-inflammatory Drugs: New Aspects o f Ap­ plication in Rheumatology and Cardiology. Russkii Medicinskii Zhurnal. 2003; 11(23): 1280-1284. (In Russ.). 45. К аратеев A .E ., Н а со н о в Е .Л ., И в аш ки н В .Т ., М ар ты н о в А .И . , Яхно Н .Н ., Арутюнов Г.П. и др. Рациональное использование несте­ роидных противовоспалительных препаратов. Клинические рекомен­ дации . Научно-практическая ревматология. 2018;56( 1): 1-29.

8 . Martin TM , Smith J R, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Current Opin­ ion in Rheumatology. 2002; 14(4):337-341. https://doi.org/10.1097/00002281-200207000-00001 9. Feldtkeller E. Age at disease onset and delayed diagnosis o f spondyloarthrop­ 10. Rozenbaum ST. Caracterization o f uveitis associated with spondyloarthritis. The Journal o f rheumatology. 1989; 16(6):792-796. 11. Будзинская M.B., Ш еланкова A.B., Плюхова A.A., Нуриева Н.М ., Со­ рокин А.С. Роль стероидов в терапии макулярного отека у пациентов с ретинальными окклю зиями . Офтальмологии. 2019; 16( 1) :9 5 -101. Budzinskaya MV, Shelankova AV, Plukhova AA, Nuriyeva NM , Sorokin AS. The Role o f Steroids in the Management o f Macular Edema from Retinal Vein Occlusion. OftaTmologiya. 2019; 16( 1) :9 5 -101. (In Russ.). https://doi.org/10.18008/1816-5095-2019-l-95-101 12. Струков А .И ., Серов В.В. Патологическая анатомия. М.: Медицина; 1995. StrukovA I, Serov W . Patologicheskayaanatomiya. М.: Medicina; 1995. (In Russ.). 13. Ahuja M. Dhake AS, Sharma SK, Majumdar DK. Topical Ocular Delivery 14. Amico C, Yakimov M, Catania MV, Giuffrida R, Pistone M, Enea V. Dif­ ferential expression o f cyclooxidenase - 1 and cyclooxigenase — 2 in the cor­ nea during wound healing. Tissue Cell. 2004;36( 1): 1-12. https://doi.Org/10.1016/j.tice.2003.08.001 15. Radi ZA, Render JA. The pathophysiologic role o f cyclo-oxigenases in the eye. J Ocul Pharmacol Ther. 2008;24(2): 141-151. https://doi.org/10.1089/jop.2007.0078 16. Ju WK, Neufeld AH. Cellular localization o f cyclooxygenase -1 and cyclo- oxygenase-2 in the normal mouse, rat, and human retina. J Comp Neurol. 2002;452(4):392-399. https://doi.org/10.1002/cne.10400 17. Chin MS, Nagineni CN , Hooper LC, Detrick B, Hooks JJ. Cyclooxygen- ase - 2 gene expression and regulation in hum an retinal pigment epithelial cells. Invest Ophthalmol VisSci. 2001 ;42( 10):2338-2346. 18. Oka T, Shearer TR , Azuma M. Involvement o f cyclooxigenase-2 in rat m od­ els o f conjunctivitis. Curr Eye Res. 2004;29( l):27-34. https://doi.org/10.1080/02713680490513164 19. Chandrasekharan NV. Hu L, Lam a rTRK , Natan K, Evanson K, Tomsik J. Elton TS, Simmons DL. COX-3, a cyclooxigenase-1variant inhibited by ac­ etam inophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS\ 2002; 19. h ttp s ://do i .o rg /10 .1073/pnas. 162468699 20. Guex-Crosier Y. Non-steroidal anti-inflammatory drugs and ocu lar inflam­ mation. Klin Monbl Augenheilkd. 2001;218(5):305-308. h ttp s ://do i.o rg /10 .1055/s-2001 -15886 21. Park GY, Cristman JW. Nuclear factor Kappa В is a promising therapeutic target in inflammatory lung disease. Cur drug Targets. 2006;7(6):661 - 668 . 22. Lee 1, Jung W, Choi Y, Kim Y. The effects o f steroids and nonsteroidal an ti­ inflammatory agents on proliferation o f human ocular fibroblast. J Korean Ophthalmol Soc. 1999;40:1496-1502. 23. Nowak J. Non-steroidal anti-inflammatory drugs (NSA1 Ds) in ophthalmol­ ogy: pharmacological and clinical characteristics. Mil Pharm Med. 2012; 5(4):33-50. 24. Yousufzai SY, Zheng P, Abdel-Latif AA. Muscarinic stimulation o fa rach i- donic acid release and prostaglandin synthesis in bovine ciliary muscle: pros­ taglandins induce cyclic AMP formation and muscul relaxation. Exp Eye Res. 1994;58(5):513-522. https://doi.org/10.1006/exer.1994.1045 25. Разумова И .Ю ., Воробьева O.K.. Годзенко А.А. Диагностика и лече­ ние HLA-B27 а ссоциированны х увеитов. Вестник офтальмологии. 2009; 125(3): 15-18. Razumova 1Y, Vorob’cva OK, Godzenko AA. Diagnosis and treatment of HLA-B27 — associated uveitis. Vestnik oftal'mologii. 2009; 125(3): 15-18. (In Russ.). 26. McChee CN , Dean S, Danesh-Meyer H. Locally administered ocular cor­ ticosteroids: benefits and risk. Drugs Saf. 2002;25( l):33-55. https://doi.org/10.2165/00002018-200225010-00004 27. Flach AJ. Topical nonsteroidal an ti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11. 28. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmol­ o f NSAlDs. AAPS.J. 2008; I0(2):229-241. h ttps ://do i.o rg /l0 .1208 /s l2248-008-9024-9 athies. ZReumatol. 1999;58( 1):21-30. https://doi.org/10.1007/s003930050149

ogy. Ophthalmologica. 2003;217:89-98. h ttps://do i.o rg /l0 .ll59 /000068563

76

ВЕСТНИК ОФТАЛЬМОЛОГИИ 6, 2020